Q2 2023: Weak underlying market in the Americas and EMEA

• Net sales decreased by 18% (21% adjusted for currency effects) to SEK 144 m (175).
• The EBITDA margin amounted to 9% (26) and was burdened by items affecting comparability. Adjusted for these, the EBITDA margin was 17%.
• Approval of HEAL9™ in Thailand. Enables further expansion in APAC.
• Takeover of distribution of our own brand Probi® in Sweden and entry into Norway with new agreements with pharmacies.
• Exclusive distributor of BLIS K12™ and BLIS M18™ ingredients in the US and Canada as of August 1.
• New partnership with Clasado Biosciences for the development of synbiotics.

Read the entire interim report here.

Invitation to teleconference

Probi's interim report for Q2 2023 will be published on July 18, 2023, at 8:00 a.m. On the same day at 10:00 a.m., a teleconference will be held with Anita Johansen, CEO and Henrik Lundkvist, CFO, who will present the report. The telephone conference can be accessed via the link https://conference.financialhearings.com/teleconference/?id=200845. The presentation is available at www.probi.com and www.financialhearings.com.